

# EXAMPLES OF NOTABLE REFERENCES ON: VRSA, GISA, hGISA

---

1. Charles, P.G., Ward, P.B., Johnson, P.D., Howden, B.P., and Grayson, M.L. (2004). Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate *Staphylococcus aureus*. *Clin Infect Dis.* 38(3): 448-51.
2. Cosgrove, S.E., Carroll, K.C., and Perl, T.M. (2004). *Staphylococcus aureus* with reduced susceptibility to vancomycin. *Clin Infect Dis.* 39(4): 539-45.
3. Charlesworth, R., Warner, M., Livermore, D.M., and Wilson, A.P. (2006). Comparison of four methods for detection of teicoplanin resistance in methicillin-resistant *Staphylococcus aureus*. *J Antimicrob Chemother.* 58(1): 186-9.
4. Diederer, B.M., van Duijn, I., Willemsse, P., and Kluytmans, J.A. (2006). In vitro activity of daptomycin against methicillin-resistant *Staphylococcus aureus*, including heterogeneously glycopeptide-resistant strains. *Antimicrob Agents Chemother.* 50(9): 3189-91.
5. Levine, D.P. (2006). Vancomycin: a history. *Clin Infect Dis.* 42 Suppl 1: S5-12.
6. Moellering, R.C., Jr. (2006). Vancomycin: a 50-year reassessment. *Clin Infect Dis.* 42 Suppl 1: S3-4.
7. Sancak, B., Ercis, S., Menemenlioglu, D., Colakoglu, S., and Hascelik, G. (2005). Methicillin-resistant *Staphylococcus aureus* heterogeneously resistant to vancomycin in a Turkish university hospital. *J Antimicrob Chemother.* 56(3): 519-23.
8. Maor, Y., Rahav, G., Belausov, N., Ben-David, D., Smollan, G., and Keller, N. (2007). Prevalence and characteristics of heteroresistant vancomycin-intermediate *Staphylococcus aureus* bacteremia in a tertiary care center. *J Clin Microbiol.* 45(5): 1511-4.
9. Sakoulas, G., Alder, J., Thauvin-Eliopoulos, C., Moellering, R.C., Jr., and Eliopoulos, G.M. (2006). Induction of daptomycin heterogeneous susceptibility in *Staphylococcus aureus* by exposure to vancomycin. *Antimicrob Agents Chemother.* 50(4): 1581-5.
10. Appelbaum, P.C. (2006). The emergence of vancomycin-intermediate and vancomycin-resistant *Staphylococcus aureus*. *Clin Microbiol Infect.* 12 Suppl 1: 16-23.
11. Wootton, M., Walsh, T.R., and MacGowan, A.P. (2005). Evidence for reduction in breakpoints used to determine vancomycin susceptibility in *Staphylococcus aureus*. *Antimicrob Agents Chemother.* 49(9): 3982-3.
12. Nunes, A.P., Teixeira, L.M., Iorio, N.L., Bastos, C.C., de Sousa Fonseca, L., Souto-Padron, T., et al. (2006). Heterogeneous resistance to vancomycin in *Staphylococcus epidermidis*, *Staphylococcus haemolyticus* and *Staphylococcus warneri* clinical strains: characterisation of glycopeptide susceptibility profiles and cell wall thickening. *Int J Antimicrob Agents.* 27(4): 307-15.
13. Wootton, M., Howe, R.A., Walsh, T.R., Bennett, P.M., and MacGowan, A.P. (2002). In vitro activity of 21 antimicrobials against vancomycin-resistant *Staphylococcus aureus* (VRSA) and heteroVRSA (hVRSA). *J Antimicrob Chemother.* 50(5): 760-1.
14. Borg, M.A., Zerafa, R., Morrison, D., and Cuschieri, P. (2005). Incidence of glycopeptide hetero-intermediate *Staphylococcus aureus* strains in Maltese hospitals. *Clin Microbiol Infect.* 11(5): 405-7.
15. Goldstein, F.W., Atoui, R., Ben Ali, A., Nguyen, J.C., Ly, A., and Kitzis, M.D. (2004). False synergy between vancomycin and beta-lactams against glycopeptide-intermediate *Staphylococcus aureus* (GISA) caused by inappropriate testing methods. *Clin Microbiol Infect.* 10(4): 342-5.
16. Cui, L., Iwamoto, A., Lian, J.Q., Neoh, H.M., Maruyama, T., Horikawa, Y., et al. (2006). Novel mechanism of antibiotic resistance originating in vancomycin-intermediate *Staphylococcus aureus*. *Antimicrob Agents Chemother.* 50(2): 428-38.
17. Tenover, F.C., Biddle, J.W., and Lancaster, M.V. (2001). Increasing resistance to vancomycin and other glycopeptides in *Staphylococcus aureus*. *Emerg Infect Dis.* 7(2): 327-32.
18. Rybak, M.J., Cha, R., Cheung, C.M., Meka, V.G., and Kaatz, G.W. (2005). Clinical isolates of *Staphylococcus aureus* from 1987 and 1989 demonstrating heterogeneous resistance to vancomycin and teicoplanin. *Diagn Microbiol Infect Dis.* 51(2): 119-25.

19. Bolmström, A., Karlsson, Å., Mills, K., Ho, P., Fang, H., and Hedin, G. First Report of Hetero-GISA among Genetically Diverse MRSA Isolated from 1996 to 2005 in Southern Stockholm, Sweden. ICAAC. (2005) New Orleans, LA,USA. C2-302
20. Perdelli, F., Dalleria, M., Cristina, M.L., Sartini, M., Ottria, G., Spagnolo, A.M., et al. (2008). A new microbiological problem in intensive care units: environmental contamination by MRSA with reduced susceptibility to glycopeptides. *Int J Hyg Environ Health*. 211(1-2): 213-8.
21. Sievert, D.M., Rudrik, J.T., Patel, J.B., McDonald, L.C., Wilkins, M.J., and Hageman, J.C. (2008). Vancomycin-resistant *Staphylococcus aureus* in the United States, 2002-2006. *Clin Infect Dis*. 46(5): 668-74.
22. Tenover, F.C. (2008). Vancomycin-resistant *Staphylococcus aureus*: a perfect but geographically limited storm? *Clin Infect Dis*. 46(5): 675-7.
23. Tenover, F.C. (2005) The real vancomycin-resistant *Staphylococcus aureus* has arrived. in *Clinical Microbiology Newsletter*. Elsevier. 27. p. 35-39.
24. Betchel, B. (2004) CDC reports third case of VRSA. in *Infectious Disease News*. May. p. 42-43.
25. Tenover, F.C., Weigel, L.M., Appelbaum, P.C., McDougal, L.K., Chaitram, J., McAllister, S., et al. (2004). Vancomycin-resistant *Staphylococcus aureus* isolate from a patient in Pennsylvania. *Antimicrob Agents Chemother*. 48(1): 275-80.
26. CDC (2004) Vancomycin-resistant *Staphylococcus aureus* - New York, 2004. in *MMWR*. 53. p. 322-323.
27. CDC (2002) Vancomycin-resistant *Staphylococcus aureus* - Pennsylvania, 2002. in *MMWR*. 51. p. 902.
28. CDC (2004) Investigation and control of Vancomycin-intermediate and -resistant *Staphylococcus aureus* (VISA/VRSA). April. p.
29. CDC (2002) *Staphylococcus aureus* resistant to vancomycin-United States, 2002. in *MMWR*. 51. p. 565-567.
30. Howden, B.P., Johnson, P.D., Ward, P.B., Stinear, T.P., and Davies, J.K. (2006). Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant *Staphylococcus aureus* bacteremia. *Antimicrob Agents Chemother*. 50(9): 3039-47.
31. Howden, B.P., Ward, P.B., Charles, P.G., Korman, T.M., Fuller, A., du Cros, P., et al. (2004). Treatment outcomes for serious infections caused by methicillin-resistant *Staphylococcus aureus* with reduced vancomycin susceptibility. *Clin Infect Dis*. 38(4): 521-8.
32. Howden, B.P., Smith, D.J., Mansell, A., Johnson, P.D., Ward, P.B., Stinear, T.P., et al. (2008). Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant *Staphylococcus aureus* bacteraemia. *BMC Microbiol*. 8: 39.